The Journal of Urology
Volume 184, Issue 2 , Pages 488-493 , August 2010

Prostate Specific Antigen Mass Ratio Potential as a Prostate Cancer Screening Tool

Received 23 November 2009

References 

  1. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156
  2. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009;53:171
  3. Denis LJ, Murphy GP, Schroder FH. Report of the consensus workshop on screening and global strategy for prostate cancer. Cancer. 1995;75:1187
  4. Schroder FH, Roobol MJ. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol. 2009;19:227
  5. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542
  6. Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56:255
  7. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101:894
  8. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005;103:1092
  9. Barqawi AB, Golden BK, O'Donnell C, et al. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology. 2005;65:708
  10. Kristal AR, Chi C, Tangen CM, et al. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106:320
  11. Osuna JA, Gomez-Perez R, Arata-Bellabarba G, et al. Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. Arch Androl. 2006;52:355
  12. Parekh N, Lin Y, Marcella S, et al. Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev. 2008;17:2467
  13. Kaaks R, Lukanova A, Rinaldi S, et al. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev. 2003;12:309
  14. Fowke JH, Matthews CM, Buchowski MS, et al. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis. 2008;11:264
  15. Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev. 2007;16:70
  16. Grubb RL, Black A, Izmirlian G, et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009;18:748
  17. Rundle A, Neugut AI. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate. 2008;68:373
  18. Rundle A, Richards C, Neugut AI. Body composition, abdominal fat distribution, and prostate-specific antigen test results. Cancer Epidemiol Biomarkers Prev. 2009;18:331
  19. Banez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298:2275
  20. Ochiai A, Fritsche HA, Babaian RJ. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology. 2005;66:819
  21. Chung BH, Hong SJ, Cho JS, et al. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int. 2006;97:742
  22. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412
  23. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known (1916). Nutrition. 1989;5:303
  24. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol. 1984;247:F632
  25. Han JH, Chang IH, Ahn SH, et al. Association between serum prostate-specific antigen level, liver function tests and lipid profile in healthy men. BJU Int. 2008;102:1097
  26. Fowke JH, Motley SS, Cookson MS, et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis. 2007;10:137
  27. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909
  28. Park JH, Cho BL, Kwon HT, et al. Effect of body mass index and waist circumference on prostate specific antigen and prostate volume in a generally healthy Korean population. J Urol. 2009;182:106
  29. du Raan H, Lotter MG, Harris GW, et al. Measurement of plasma volume using 99Tc(m)-labelled DMP-HSA. Nucl Med Commun. 2000;21:539

 Supplementary material for this article can be obtained at http://hpc.snuh.org/_Control/skin/2/download.jsp?file_name1=JU-09-2042[1]_attached_table.pdf.

 Study received institutional review board approval.

PII: S0022-5347(10)03265-9

doi: 10.1016/j.juro.2010.03.138

The Journal of Urology
Volume 184, Issue 2 , Pages 488-493 , August 2010

Article Tools